There are oral drugs for the treatment of neuroendocrine tumors, such as everolimus, sunitinib, sofantinib, etc. However, not all neuroendocrine tumors are suitable for oral drugs, which need to be selected according to the actual situation. Everolimus is suitable for adult patients with unresectable, locally advanced or metastatic medium-highly differentiated pancreatic neuroendocrine tumors. Adverse reactions such as stomatitis, malaise, infection, diarrhea, and cough can be seen, and those who are allergic to the drug are prohibited, and the tablets need to be swallowed whole during administration, and should not be crushed or chewed. Sunitinib for unresectable, metastatic highly differentiated pancreatic neuroendocrine tumors in adult patients, can be seen in blood uric acid elevation, infection, thrombocytopenia and other adverse reactions, allergic to the drug is prohibited, and food with or without serving can be. Sofantinib is used for inoperable resectable locally advanced or metastatic, progressive non-functional, well-differentiated (G1, G2) neuroendocrine tumors of non-pancreatic origin. Other oral medications may be available for neuroendocrine tumors, such as etoposide, which can be given orally for small cell neuroendocrine tumors. Although oral drugs are convenient to use, all of the above drugs are prescribed for antitumor therapy and have their own characteristics and side effects, so they must be applied under the guidance of a doctor, not on their own.